Business

Original source (on modern site) | Article images: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14]

Highlights

1. It Introduced Ozempic to the World. Now It Must Remake Itself.

   Novo Nordisk's factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.

    By Eshe Nelson and Charlotte de la Fuente

   Credit

2. How Ozempic Is Transforming a Small Danish Town

   In Kalundborg, population under 17,000, Novo Nordisk is making huge investments to increase production of its popular diabetes and weight-loss drugs, Ozempic and Wegovy.

    By Eshe Nelson

   CreditCharlotte de la Fuente for The New York Times

3. 1. VW Workers in Tennessee Vote for Union, a Labor Milestone

      The Volkswagen plant in Chattanooga is set to become the first unionized auto factory in the South not owned by one of Detroit's Big Three.

       By Neal E. Boudette

      CreditGeorge Walker IV/Associated Press

   2. news analysis

      Could the Union Victory at VW Set Off a Wave?

      Some experts say the outcome at a plant in Chattanooga, Tenn., may be organized labor's most significant advance in decades. But the road could get rockier.

       By Noam Scheiber

      CreditOlivia Ross/Chattanooga Times Free Press, via Associated Press

1. Credit

2. CreditRobert Neubecker

   Your money

3. CreditGili Benita for The New York Times

   retiring

4. CreditThomas Fuchs

   your money adviser

5. Can the W.N.B.A. Make Money?

   A wave of star power has lifted hopes that viewership will pick up for the women's league.

    By Lauren Hirsch, Tania Ganguli and Sarah Kessler

   CreditBrad Penner/USA TODAY Sports

   DealBook Newsletter

• Latest

• Search

5. TimesVideo

   Inside Novo Nordisk's Headquarters

   Ozempic and Wegovy, the diabetes and weight-loss drugs, have soared to celebrity status in the U.S. But Novo Nordisk, the Danish company behind them, can't make enough of them. The New York Times reporter Eshe Nelson went to the drugmaker's headquarters to see how the company is transforming to deal with the global fame and demand.

   By Nikolay Nikolov, Eshe Nelson and Charlotte de la Fuente